Introduction: Osimertinib showed great clinical efficacy for activated-EGFR NCLC patient treatment. The aim of this work was to test the efficacy of a complete EGFR-inhibition by osimertinib plus the monoclonal antibody cetuximab or the MEK1/2-inhibitor selumetinib in EGFR-mutated NCLC in vivo models. Methods: We evaluated combinations of osimertinib plus selumetinib/cetuximab in HCC827 (E746-A759del/T790M-), H1975 (L858R/T790M+), and PC9-T790M (E746-A759del /T790M+) xenografts in second-line therapy after the development of resistance to osimertinib, and in first-line therapy, and we explored mechanisms of resistance to these treatments. Results: The addition of selumetinib or cetuximab to osimertinib in second-line therapy reverted ...
none13siPurpose: Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine...
Patients with advanced epidermal growth factor receptor ( EGFR ) mutant non-small cell lung cancer (...
Introduction: EGFR tyrosine kinase inhibitors (TKIs) are recommended for EGFR-mutated NSCLC treatmen...
Introduction: Osimertinib showed great clinical efficacy for activated-EGFR NCLC patient treatment. ...
Introduction: Osimertinib showed great clinical efficacy for activated-EGFR NCLC patient treatment. ...
Background: The third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (...
Introduction: Osimertinib is a third-generation anti-epidermal growth factor receptor (EGFR) tyrosin...
PURPOSE: The epidermal growth factor receptor (EGFR) autocrine pathway plays an important role in ca...
Introduction: EGFR tyrosine kinase inhibitor improved the survival of patients with metastatic EGFR ...
Purpose: We investigated the effect of triple monoclonal antibody inhibition of EGFR to overcome acq...
Purpose: Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine kinase ...
Purpose: Approximately one-third of patients with non-small cell lung cancer (NSCLC) harboring tumor...
Purpose: The epidermal growth factor receptor (EGFR) autocrine pathway plays an important role in ca...
<b>Purpose:</b> Because of emergence of resistance to osimertinib, a third-generation E...
PURPOSE: Cancer cell survival, invasion and metastasis depend on cancer cell proliferation and on tu...
none13siPurpose: Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine...
Patients with advanced epidermal growth factor receptor ( EGFR ) mutant non-small cell lung cancer (...
Introduction: EGFR tyrosine kinase inhibitors (TKIs) are recommended for EGFR-mutated NSCLC treatmen...
Introduction: Osimertinib showed great clinical efficacy for activated-EGFR NCLC patient treatment. ...
Introduction: Osimertinib showed great clinical efficacy for activated-EGFR NCLC patient treatment. ...
Background: The third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (...
Introduction: Osimertinib is a third-generation anti-epidermal growth factor receptor (EGFR) tyrosin...
PURPOSE: The epidermal growth factor receptor (EGFR) autocrine pathway plays an important role in ca...
Introduction: EGFR tyrosine kinase inhibitor improved the survival of patients with metastatic EGFR ...
Purpose: We investigated the effect of triple monoclonal antibody inhibition of EGFR to overcome acq...
Purpose: Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine kinase ...
Purpose: Approximately one-third of patients with non-small cell lung cancer (NSCLC) harboring tumor...
Purpose: The epidermal growth factor receptor (EGFR) autocrine pathway plays an important role in ca...
<b>Purpose:</b> Because of emergence of resistance to osimertinib, a third-generation E...
PURPOSE: Cancer cell survival, invasion and metastasis depend on cancer cell proliferation and on tu...
none13siPurpose: Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine...
Patients with advanced epidermal growth factor receptor ( EGFR ) mutant non-small cell lung cancer (...
Introduction: EGFR tyrosine kinase inhibitors (TKIs) are recommended for EGFR-mutated NSCLC treatmen...